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A B S T R A C T
Purpose: Controlled-release formulations of Valproate (VPA) reduce side effects by minimizing peak
plasma VPA concentrations in patients with epilepsy. However, the impact of this on anti-seizure
efﬁcacy has not been thoroughly explored. Here the pharmacokinetics and pharmacodynamics of
chronic intermittent (consequently, peak VPA concentrations) and continuous VPA administration were
directly compared in two rat models of epilepsy.
Methods: Genetic Absence Epilepsy Rats from Strasbourg (GAERS) received a single acute bolus of VPA
(100 mg/kg intravenously) combined with electroencephalography (EEG) and/or blood sampling for
180min post-injection. GAERS and epileptic rats post-kainic acid-induced status epilepticus were
chronically infused intravenously (3–5 days, respectively) with (i) saline followed by in random order (ii)
intermittent and (iii) continuous VPA (42mg/kg/h), separated by two days of wash-out. Seizures were
quantiﬁed using video-EEGmonitoring and VPA levels measured in brain, cerebrospinal ﬂuid and plasma.
Results: Following acute VPA administration seizure suppression in GAERS persisted after plasma VPA
levels became very low. Chronic intermittent and continuous VPA signiﬁcantly suppressed seizures in
both models (p < 0.01) with no difference between administration regimens. In GAERS, the pattern of
seizure suppression during intermittent treatment was constant, in contrast to the ﬂuctuating VPA
plasma and brain levels. There was discordance between the temporal pattern of plasma, brain VPA
levels and seizure suppression efﬁcacy in GAERS.
Conclusion: Administration regimes that result in ﬂuctuating VPA blood levels achieve equivalent
sustained seizure suppression as those that maintain steady mid-range concentrations.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Valproate (valproic acid, VPA) is one of the most widely used
anti-epileptic drugs (AED) in clinical practice world-wide, with a
broad-spectrum of activity across different seizure types in both
children and adults.1 It is generally regarded as the drug of
choice for the control of all types of generalised epilepsy
syndromes,2 but is also effective in the treatment of partial
seizures, with or without secondary generalisation, and acutely
in status epilepticus.3 However, concerns around its tolerability* Corresponding author. Tel.: +61 3 83 3260; fax: +61 3 93471863.
E-mail addresses: stefanie.dedeurwaerdere@hotmail.com (S. Dedeurwaerdere),
lvanraay@unimelb.edu.au (L. van Raay), m.morris@unsw.edu.au (M.J. Morris),
reedrc@husson.edu (R.C. Reed), hogane@neuro.wustl.edu (R.E. Hogan),
obrientj@unimelb.edu.au (T.J. O’Brien).
1 Formerly at Abbott R&D.
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.10.011(e.g. sedation and weight gain),4,5 teratogenicity in pregnant
women6,7 and potential for serious organ toxicity (e.g. hepato-
toxicity and pancreatic toxicity)8,9 inﬂuence the use of VPA in
clinical practice.
Minimizing peak concentrations by administering VPA in an
extended-release preparation, resulting in less ﬂuctuations in
plasma concentrations10 has been advocated as an approach to
reduce side effects.11 Indeed, extended-release divalproex sodium,
especially engineered for slow release over 24 h, signiﬁcantly
decreased side effects in epilepsy patients.12 Another advantage of
sustained release VPA formulations over conventional formula-
tions is the reduced dosing frequency required (i.e. once daily),
potentially aiding patient compliance.13 In animal models of
embryo toxicity testing, high peak plasma levels (i.e. Cmax) of VPA,
but not the total daily dose, correlated with the incidence of neural
tube defects.14
‘However, the impact on seizure control of the higher peak
and lower trough serum levels of VPA that result from traditionalvier Ltd. All rights reserved.
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speciﬁc scientiﬁc study. Lower trough levels may potentially be
associated with an increased risk of breakthrough seizures.
Conversely, it has been suggested that peak VPA levels may be
necessary to achieve optimal anti-epileptic efﬁcacy.11,15 The
primary mechanisms by which VPA exerts its anti-seizure effects
are still uncertain. In vitro neurophysiological experiments show
that VPA has an early effect to inhibit cellular excitability which
is exerted from the extracellular side of the neuronal membrane,
and a late effect resulting from intracellular actions of VPA which
is delayed at least in part because of slow penetration of VPA into
neurons.16,17 The latter effect might beneﬁt from high peak VPA
levels promoting diffusion into neurons.18 However, a random-
ised control study in humans using divalproex extended-release
formula, indicates that there is no loss of seizure control.19 In
animals, it has been demonstrated that conventional VPA
administration (dose resulting in peak concentrations) is not
necessary to achieve anticonvulsant action in the pentylenetet-
razol (PTZ)-infusion seizure threshold model.18 Furthermore,
continuous administration of VPA resulted in higher tolerability
and fewer side effects.
In the experiments reported here, two rat models displaying
spontaneous seizures were used in which clear VPA antiepileptic
effects have been demonstrated previously.20–23 Genetic Absence
Epilepsy Rats from Strasbourg (GAERS) and the status epilepticus
(SE) model are both well validated models of genetic generalised20
and acquired limbic epilepsy,24 respectively. Testing efﬁcacy in
models of these distinct forms of epilepsy is relevant because AEDs
may have differential effects on different types of epilepsy,25 and
these models represent the two most common broad groups of
human epilepsies. Of particular importance for this study, GAERS
have a high seizure frequency (on average every 1–2 min) which
enables the temporal relationship between plasma VPA levels and
anti-seizure efﬁcacy to be investigated. A better understanding of
the effect of plasma VPA ﬂuctuations on brain penetration and
anti-seizure efﬁcacy has implications for the design and delivery of
oral formulations in clinical practice. Therefore, the aims of this
study were to compare intermittent (with attendant peak VPA
concentrations) versus constant intravenous (i.v.) VPA adminis-
tration in two rodent models of epilepsy for: (i) anti-seizure
efﬁcacy, (ii) plasma and cerebrospinal ﬂuid (CSF) concentrations
and (iii) brain penetration.
2. Methods
2.1. Animals
Rats were bred at the Ludwig Institute for Cancer Research
and the Biological Research Facility (the Royal Melbourne
Hospital). Temperature was controlled to a constant 22 8C and
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Fig. 1. Overview of the experimental design for GAERSanimals were put on a 12 h light/dark cycle with ad libitum food
and water. One week before experimentation rats were
individually housed. All experiments were approved by the
Melbourne Health Animal Ethics Committee (project 2006.035),
the University of Melbourne Animal Ethics Committee and
followed the Principles of Laboratory Animal Care (NIH publica-
tion No. 86-23 revised 1996).
Twenty one male (338  5 g) and 7 female (225  16 g) 4 month
old GAERS and 22 male non-epileptic control (NEC) rats 9–10 weeks
old (391  7 g) were used. All NEC rats were treated with repeated
low-dose injections of KA (5–10 mg/kg, OPIKA-1TM Ocean Produce
International, Shelburne, Canada) until SE was induced.26 SE was
deﬁned as a period of continuous seizures sustained for 4 h and
terminated with diazepam (Mayne Pharma, Adelaide, Australia)
(4 mg/kg) as previously described.27,28
2.2. Study design
The study consisted of three experimental parts: (i) an acute
single bolus study in GAERS, (ii) a chronic infusion study in GAERS
and (iii) a chronic infusion study in post-KA SE rats.
(i) The acute single bolus administration study in GAERS: 12
GAERS received a single dose of VPA (100 mg/kg) i.v., via a
previously implanted jugular vein cannula, with the animal
moving freely in its home case. This dose was chosen on the
basis of previous studies that had demonstrated signiﬁcant
seizure suppression with the use of this dose as an acute bolus
injection in GAERS.29 EEG was recorded for 1 h before and 3 h
after each bolus using Compumedics ProFusion EEG acquisi-
tion software (Melbourne, Australia). Bloodwas taken (0.1 mL)
from 5 GAERS: 2, 5, 30, 60, 120, 180 min post-VPA
administration for analysis of VPA plasma levels.
(ii) The chronic infusion study inGAERS (Fig. 1): 16 rats (9male, 7
female) were ﬁrst continuously infused for 4 days with 0.9%
saline i.v. (1 mL/h) followed by in random order (cross-over)
two serial VPA treatment regimens each 3 days long:
intermittent infusions (42 mg/kg/1 mL over 4 min every
hour) or continuous VPA infusion (42 mg/kg/1 mL/h) sepa-
rated by a 2 day wash-out period of saline (1 mL/h). EEG was
acquired on day 3 of each treatment regimen for 24 h. The last
24 h of the chronic infusion treatment periods were chosen
for the EEG analysis in the GAERS study because this
represented a time period in which steady-state equilibrium
plasma levels are reached, and best represented the situation
of patients chronically taking VPA. To investigate long-lasting
effects of chronic VPA treatment, EEG was also acquired for
the ﬁrst 24 hof thewash-out period in eight animals (four had
received the continuous VPA regimen and four the intermit-
tent regimen).hronic drug infusion in GAERS
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a similar protocol consisting of VPA infusion and continuous
24 h video-EEG monitoring. Twenty-two animals received
saline for 5 days, and intermittent and continuous VPA for
4.5 days each (in a randomised order, cross-over). Twelve
animals did not display spontaneous seizures during the saline
period and one animal did not complete the study due to being
unwell; these animals were excluded from the analysis
A blood sample was taken in a subgroup of rats at the end of the
washout period.
2.3. Surgery
EEG electrodes were implanted under ketamine/xylazine
anaesthesia in a stereotaxic frame as described previously.28
During surgery, heart rate and blood oxygen levels weremeasured.
GAERS received 6 epidural electrodes and post-KA SE rats received
4 epidural electrodes and some also a bipolar electrode into the left
hippocampus (coordinates from bregma: anterioposterior –
4.6 mm, mediolateral – 5.8 mm, dorsoventral – 7 mm). A 9-pin
ABS plug (GS09PLG-220, Ginder Scientiﬁc, Canada)30 was used to
ﬁx the electrodes and to hold the PVC jugular vein cannula (JVC).
Saline (0.9% NaCl, 1 mL, s.c.) was administered to prevent
dehydration and carprofen (5 mg/kg, Pﬁzer, Australia) was injected
i.p. for pain relief at the end of each surgery. Animalswere returned
to their home cages for recovery.
Two weeks later a JVC (internal diameter = 0.8 mm, outside
diameter = 1.2 mm, Microtube Extrusions Pty Ltd, North Rocks,
Australia) was implanted under isoﬂurane anaesthesia as de-
scribed previously.28 The EEG/infusion cable and head cap were
locked together via a Delrin Ring Nut (GS09BDN-220, Ginder
Scientiﬁc, Nepean, Canada).28 Carprofen (5 mg/kg, Pﬁzer, West
Ryde, Australia) was injected i.p. at the end of surgery for pain
relief. The animals were placed into their experimental cage to
recover and saline infusion commencedwithin 1–3 h post-surgery.
2.4. Drug delivery
Valproate in the form of valproic acid sodium salt (Sigma–
Aldrich, St. Louis, USA) was dissolved in saline (0.9% NaCl, 5 mL/kg)
at two different doses. The concentration of the single acute bolus
study was 100 mg/kg and for the chronic infusion study 42 mg/kg/
h containing 4 IU/mL Heparin (Heparin Sodium DBL, Hameln
Pharmaceuticals GmbH, Hameln, Germany). The latter dose has
previously been administered i.v. and was found to produce
therapeutic serum levels of VPA (600–1800 mmol/L).31
Drug delivery was carried out via an EEG/infusion cable
(made in house) connected through an EEG and ﬂuid swivel,
allowing free movement, to a 32 channel video-EEG system(Compumedics Limited, Melbourne, Australia) and a multi-
syringe programmable pump (KDS 230, Walker Scientiﬁc,
Wangara, Australia) as previously described.28 To assist in
preventing infusion lines clotting, animals were given a daily
0.1 mL bolus of heparinised saline (20 IU/mL). Any leakages or
blockages were ﬁxed if possible, and if not, the rat was removed
from the study for the treatment arm they did not complete and
euthanased (one GAERS received intermittent only and two
others continuous infusion only).
2.5. Plasma, CSF and brain VPA levels
At the end of the chronic infusions animals were euthanased 5
(n = 4), 30 (n = 5) and 55 (n = 5) min post-bolus or during
continuous infusion (n = 13) using a Lethabarb overdose
(325 mg pentobarbitone sodium, i.p., Virbac Animal Health, Carros
Cedex, France). When rats were fully anaesthetised a cerebral
spinal ﬂuid (CSF) sample (0.1 mL) was extracted from the cisterna
magna area, which was successful in most animals, some samples
were contaminated with blood and thus discarded. Blood (1 mL)
was sampled from the heart to investigate VPA plasma levels and
was centrifuged at 8000 rpm for 5 min. Plasma VPA analysis was
carried out on an Abbott TDX system (analytical range: 5–
1040 mmol/L using Fluorescence Polarization Immunoassay)
(Abbott Diagnostics, Abbott Park, USA).
Subsequently the rat brain was rapidly removed and dissected
into four regions: hippocampus, thalamus, cortex and the remaining
areas. Brain regionswere homogenised in a 1:1 ratio of brainweight
to distilled water (to include intracellular and extracellular VPA in
the results), except for the hippocampus, whichwas diluted in a 1:3
ratio because of the small volume of tissue comparedwith the other
brain regions. Brain homogenates were centrifuged at 12,000 rpm
for 10 min at 4 8C and the supernatant removed for VPA analysis
with the Abbott TDX system.
2.6. EEG data processing and analysis
For the acute study, seizures during the bolus study in GAERS
were quantiﬁed by reviewing the 4 h EEG recording using the
Mighty EDF1 EEG viewing software (version 1.3.3, University of
Ghent, Ghent, Belgium) and manually marking the start and the
end of the seizure. The comparison of % time in seizure pre- versus
post-treatment in GAERS was calculated by averaging four 15 min
blocks in the hour prior to the drug injection, then comparing each
subsequent 15 min block post-treatment to this baseline value.
The 24 h EEG recordings from the chronic GAERS study were
analysedusinga semi-automatedSWDdetectionprogram(SWDﬁn-
der, Radboud Universiteit, Nijmegen, The Netherlands), which we
have validated to detect SWDs with high sensitivity (100%) and
accuracy (95%) versus manual seizure identiﬁcation. The software
S. Dedeurwaerdere et al. / Seizure 20 (2011) 72–79 75highlights automaticallydetectedseizures,whichwere subsequent-
ly manually conﬁrmed and start/end of seizures was adjusted if
required.
Data from the chronic infusion is represented as % time in
seizure, total number of seizures and average seizure duration. In
addition, 24 h EEG data recorded during intermittent VPA
treatment was separated into four 15 min blocks (0–15 min,
15–30 min, 30–45 min and 45–60 min post-bolus) and expressed
as average % time in seizure. Eight animals had a 24 h EEG
recording on the ﬁrst day of the wash-out period. EEG data
acquired during the washout period was separated into six 4 h
time blocks post-cessation of VPA.
For the post-KA SE rats, spontaneous convulsive seizures were
quantiﬁed by manual review of the continuous synchronised
video-EEG recordings (ProFusion EEG v3.7, Compumedics Limited,
Melbourne, Australia). As animals were mainly displaying
convulsive seizure Class IV–V, data were expressed as number
of Class IV and V convulsive seizures according to the scale of
Racine32 per day per rat. All analysis was carried out blinded.
2.7. Statistical analysis
The EEG data was not normally distributed and therefore was
analysed using non-parametric tests. For the GAERS study, no
differences were found between male and female rats; therefore,
the data of both genders was combined. The bolus study was
analysed using a one-way ANOVA Friedman test followed by a
post hoc Dunns test for comparison of each 15 min time block of %
time in seizure post-VPA. A Friedman test was used for[()TD$FIG]
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Fig. 3. Temporal seizure suppression and VPA plasma levels after a bolus of 100 mg/kg VP
hoc Dunns test, *p < 0.05, **p < 0.01, ***p < 0.001 all compared to the corresponding base
are expressed as mean  S.E.M.comparison of absence seizures between saline, intermittent
and continuous VPA treatment, followed by a post hoc Wilcoxon
signed rank (1-tail for saline versus treatment and 2-tailed for
intermittent versus continuous). A Friedman test was used
followed by a post hoc Dunns test on convulsive seizures in
post-KA SE animals and to compare % time in seizure during four
different time blocks (15 min) post-hourly VPA infusion in the
intermittent VPA treated GAERS. AWilcoxon signed rank test was
used to compare % time in seizure of six 4 h time blocks post-VPA
treatment during the ﬁrst day of the saline wash-out period
between corresponding time points of saline and VPA infusion
conditions.
VPA levels in plasma, CSF and brain regions were normally
distributed and analysed with a one-way ANOVA followed by a
planned comparisons Bonferroni test.
Data are presented as mean  S.E.M. for the parametric tests.
Signiﬁcance was set at p < 0.05.
3. Results
3.1. Acute single bolus VPA administration in GAERS
Compared to baseline, seizures were signiﬁcantly suppressed
up to 165 min post-VPA bolus administration compared to
baseline, although this did not attain statistical signiﬁcance for
the 15 min time blocks at 90 and150 min (Fig. 3A). Corresponding
VPA plasma levels 2, 5, 30, 60, 120, 180 min are plotted in Fig. 3B.
By 120 min post-bolus the plasma VPA levels had declined to very
low levels (61 + 13 mmol/L, i.e. 1.7% of peak levels). It is90 105 120 135 150 165 180
**
*
*
*
st VPA bolus (min)
100 120 140 160 180
ost VPA bolus (min)
A. (A) % of average 15 min baseline time in seizure n = 12. Friedman test with a post
line period. (B) VPA plasma levels (mmol/L) post 100 mg/kg bolus of VPA n = 5. Data
S. Dedeurwaerdere et al. / Seizure 20 (2011) 72–7976noteworthy that seizure suppression persisted for at least another
45 min following this time point.
3.2. Chronic intermittent and continuous VPA infusion in GAERS
Both intermittent and continuous VPA treatment arms resulted
in signiﬁcantly suppressed % time in seizure (58% and 52%,
respectively, p < 0.01, Fig. 4A), mainly due to a decrease in seizure
number (p < 0.01, Fig. 4B), while the seizure duration was not
signiﬁcantly affected (Fig. 4C). There was no signiﬁcant difference
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Fig. 4. Seizure expression during chronic infusions of saline, intermittent VPA and
continuous VPA in GAERS: % time in seizures, number of seizures per 24 h andmean
duration of seizures. Box plot indicates the median with lower and upper quartile
ranges and sampleminimumandmaximumvalues. A Friedman test with a post hoc
Wilcoxon signed rank (1-tail for saline versus treatment and 2-tailed for
intermittent versus continuous) was used. **p < 0.01. Saline n = 16, continuous
VPA n = 15, intermittent VPA n = 14.between intermittent and continuous treatment regimens in %
time in seizure, number of seizures, or seizure duration.
Further analysis of the intermittent treatment regimen into
15 min time blocks demonstrated that seizure suppression did not
signiﬁcantly vary between any of the time blocks in the hour post
the bolus (Fig. 5).
No order of treatment effect was observed in the intermittent
and ﬂuctuating treatment periods for any of the seizure
characteristics (p > 0.05, data not shown).
EEG-monitoring during the ﬁrst 24 h of the wash-out period
demonstrated that seizures were being suppressed up until 20 h
post-VPA when compared to saline, with the time blocks 12–16 h
and 16–20 h reaching signiﬁcance (p < 0.05) when a Wilcoxon
signed rank test was applied to individual time blocks (Fig. 6).
3.3. Chronic intermittent and continuous VPA infusion in
post-KA SE rats
Freedom from convulsive seizures (Class IV or V) was achieved
in 9/9 post-KA animals during the chronic intermittent VPA
infusion versus 7/9 during the continuous VPA infusion. Both
chronic VPA treatment regimens were effective in suppressing
these seizures compared to the saline infusion arm (p < 0.01,
Fig. 7).
There was no signiﬁcant difference between intermittent and
continuous treatment or between the ﬁrst or second VPA
treatment periods in this cross-over study. Blood samples from
the end of the washout period contained no detectable VPA levels.
3.4. Brain, plasma and CSF VPA levels following intermittent and
continuous infusions
There was no difference observed between the rat models,
hence results were combined for this analysis. VPA thalamic and
hippocampal brain uptake, CSF and plasma concentrations were
signiﬁcantly different between the time points (ANOVA, p < 0.001,
p < 0.01, p < 0.001, p < 0.001, respectively) and approached
signiﬁcance for the cortex (ANOVA, p = 0.08) as shown in Fig. 8.
Post hoc Bonferroni analysis demonstrated that peak VPA levels
(5 min post-bolus) were signiﬁcantly higher than trough VPA
levels (55 min post-bolus administration) for thalamus, hippo-
campus, CSF and plasma (Fig. 8), with approximately a four-, ﬁve-
and three-fold difference between peak and trough brain levels,
CSF and plasma, respectively. CSF and plasma levels were
signiﬁcantly higher at 5 min post-bolus administration compared
to 30 min post-bolus and continuous administration (Fig. 8). This
conﬁrms that the intermittent protocol truly resulted in ﬂuctuat-
ing VPA concentrations. There was no signiﬁcant difference in VPA
concentration between 30 min post-bolus and continuous VPA
administration (Fig. 8).
VPA concentrations were similar for the different brain regions
(Fig. 8). Plasma concentrationswere around 3–4 times higher than
CSF values. Plasma levels were closely correlated linearly with
those of: CSF R = 0.91, cortex R = 0.86, thalamus R = 0.87, hippo-
campus R = 0.84, rest of brain R = 0.88 (p < 0.01, n = 20–27).
4. Discussion
This study evaluated the pharmacokinetics and pharmacody-
namics of acute and chronic VPA administration in two animal
models of epilepsy. We observed two major ﬁndings: (a) in the
intermittent delivery protocols, both acute and chronic, a temporal
discordance between VPA plasma levels and amount of seizure
suppression (measured in the GAERS) occurred, and (b) an
equivalent seizure reduction, as compared to saline infusion,
was achieved in both the intermittent and continuous chronic VPA
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S. Dedeurwaerdere et al. / Seizure 20 (2011) 72–79 77delivery protocols in the animal models. The results demonstrate
that a VPA administration regimen resulting in ﬂuctuating (high
peak) total VPA levels does not produce signiﬁcantly different
seizure control than a regimen that results in constant, relatively
ﬂat blood levels over a dosing interval. This indicates that repeated
high peak plasma VPA levels are not necessary for the optimal anti-
seizure effect, and that the trough periods do not result in
signiﬁcant breakthrough seizures. The likely explanation for the
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with a post hoc Dunns test. **p < 0.01. Data is shown for individual animals.apparent lack of importance of the VPA trough is the observation
that there is a temporal discordance between the blood levels and
the anti-seizure effects, indicating that VPA is, in at least part,
acting by more prolonged cellular mechanisms. Alternatively, the
VPA troughs were still above the threshold to provide maximal
anti-seizure efﬁcacy.
No signiﬁcant differences were found in the amount of seizure
suppression between any of the four averaged 15 min time blocks
post-repeated intermittent VPA boli in GAERS, despite a three- to
ﬁve-fold difference between peak and trough plasma, CSF and
brain levels (Fig. 8). Brain and CSF VPA levels correlated tightly
with plasma levels during intermittent (ﬂuctuating) and continu-
ous VPA administration. This indicates that the discordance
between the plasma levels and seizure suppression was not due
to delayed brain entry of the VPA. Furthermore, seizures were
signiﬁcantly suppressed up to 20 h following the cessation of the
chronic infusion compared with saline only treatment. Following a
single acute injection the seizures were suppressed for at least
165 min post-VPA administration, well after the VPA plasma
concentrations had declined to negligible levels (i.e. <1.7% of peak
levels 120 min post-injection). This phenomenon is sometimes
referred to as the ‘carry over effect’, and our results provide support
for this experimental33,34 and clinical observation.35 Nau and
Loscher ﬁrst described the presence of a metabolite (2-propyl-2-
pentenoic acid) which persists for at least 8 h after VPA
administration in mice, correlating well with the carry-over
effect.33 In rats this metabolite was shown to accumulate in the
brain during prolonged treatment.36 Although potentially an
accumulation of anti-convulsant metabolite in the brain could
have biased our cross-over study, we did not ﬁnd a treatment order
effect in this randomised study. This suggests that the effects of
these anti-convulsantmetabolites had largely worn off by the start
of the second treatment period.
Previous studies have also shown that there is a late intracellular
effect of VPA after slow penetration into the cells synergistic to an
acute rapid extracellular effect on neuronal membranes.16,17 The
[()TD$FIG]Fig. 8. VPA levels in brain structures, CSF and plasma during intermittent (5, 30 and
55min after bolus infusion) and continuous VPA treatment. One-way ANOVA
followed by a planned comparison Bonferroni test. *p < 0.05, **p < 0.01, ***p < 0.001;
5 minpost-bolus,n = 4,30 minpost-bolus,n = 5,55 minpost-bolus,n = 5, continuous,
n = 13. Data are expressed as mean S.E.M.
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mechanism of action of VPA.16 Indeed, VPA is known to activate
several secondary messenger systems.37,38 For example, neuropep-
tide Y (NPY), a neuropeptide with anti-epileptic properties against
experimental focal39 and generalised seizures,40,41 has been shown
to be increased in the brain after 3 days of VPA treatment, but not
after acute treatment.37 Additionally, chronic VPA administration is
now known to enhance intracellular demethylase activity through
its effects on histone acetylation resulting in long-lasting epigenetic
changes in gene expression.42,43
This study is unique in that it has investigated the relationship
between the pharmacokinetics (plasma, CSF and brain VPA levels)
and pharmacodynamics (seizure suppression) of different VPA
administration regimes in spontaneously seizing epileptic rats.
Previous studies have used acute provoked seizures in otherwise
non-epileptic animals,18 which are likely to have less relevance for
the human chronic epileptic condition. Studies using chronic
epilepsy models are more labour intensive as they require long-
term monitoring and infusion equipment.28 The GAERS model is
ideally suited for the study of pharmacokinetic-pharmacodynam-
ics of drugs as the animals express frequent spontaneous
generalised seizures, providing the temporal resolution to allow
investigation of the effect of rapid changes in drug blood levels on
seizure suppression. The post-KA SE model displays less frequent
seizures; daily to weekly seizures compared to every 1–2 min on
average in GAERS. Therefore, a longer and continuous 5 day video-
EEG monitoring period was required in the post-KA SE model. This
model does not allow the high temporal resolution of drug-seizure
effects that enabled a close examination of the pharmacokinetic-
pharmacodynamic relationships in the GAERS, but it was impor-
tant to study as the anti-seizure efﬁcacy of VPA may be less for
focal limbic seizures.1,44
In humans, VPA is most commonly administered twice a day,
with one dose roughly every half life (9–20 h).45 In rats, VPA half-
life is variable and dose dependent.38 In addition, PK/PD
relationship does not seem to be linear as exempliﬁed by the
acute bolus study in which 100 mg/kg resulted in at least >60 min
seizure suppression, while a biological half-life of 37 min was
measured. In the current study we chose to administer intermit-
tently on an hourly basis and in order to keep the total daily
dose the same in both chronic treatment arms (i.e. 1008 mg/kg per
day), 42 mg/kg/h was administered to the intermittent group. A
previous study by Arens and Pollack31 showed sustained
therapeutic plasma levels by hourly continuous infusion of
42 mg/kg of VPA. The longer time between the administration of
VPA doses (e.g. 8 h) that has been used in other studies,18 would
result in prolonged periods of low VPA levels in the intermittent
infusion group which could bias the results. On the other hand, we
did not opt for the usual very high doses of VPA (around 200 mg/
kg) used previously,38 in order to have the dynamic range to be able
to pick up effects of ﬂuctuations in VPA levels on seizure
suppression. The 3.5-fold degree of difference in peak-trough
total plasma VPA concentrations observed for our chosen chronic
intermittent i.v. regimen is greater than the almost 2-fold peak-
trough difference observed to occur for an oral immediate-release
(enteric-coated, delayed-release) divalproex sodium tablet formu-
lation in a every 8-h dosing regimen commonly used clinically10
and still more than the approximate average 2.4-fold peak-trough
difference simulated to occur for the same preparationwhen taken
every 24 h.46 Accordingly, the peak VPA levels achieved in our
study were more than sufﬁcient to answer our question as to the
contribution of peak plasma VPA (versus average concentration) to
anti-seizure efﬁcacy.
A previous study had compared intermittent and continuous
VPA administration in the acute PTZ threshold rat model.18
Continuous VPA treatment (600 mg/kg/day) signiﬁcantly de-creased PTZ seizure threshold, but bolus (200 mg/kg) followed
by infusion (400 mg/kg/day) or three bolus injections a day
(200 mg/kg) resulted in better seizure suppression. The apparent
conﬂict with the results of our study could be explained by the PTZ
threshold being tested 15 min after bolus injection (200 mg/kg), at
which time signiﬁcantly higher VPA plasma levels would be
expected compared to the continuous infusion. Even though we
did not ﬁnd in our study that VPA levels correlated well with the
degree of seizure suppression, the differences between the levels
would have been substantially greater in this previous study than
in ours given the higher dose bolus (200 versus 42 mg/kg) and
lower dose constant infusion (25 versus 42 mg/kg) used. It is also
possible that the difference in the ﬁndings represents an inherent
difference in seizure susceptibility between the chemoconvulsant
and genetic animal models used in the two studies.
In conclusion this study demonstrated, in truly epileptic animal
models manifesting spontaneous generalised or focal seizures,
that peak VPA concentrations are not required for optimal anti-
seizure efﬁcacy, with the maintenance of steady mid-range
concentrations being just as potent. Furthermore, we found a
temporal discordance between plasma, CSF and brain VPA levels
(pharmacokinetics) and anti-seizure efﬁcacy (pharmacodynamics)
with intermittent VPA administration. These results have clinical
implications, speciﬁcally regarding the use of controlled release
formulations that provide less ﬂuctuation in blood levels.
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